Robert McRae
Nessuna posizione attualmente
Patrimonio netto: 1 735 $ in data 31/03/2024
Profilo
Robert McRae worked as Vice President-Operations at Viracta Subsidiary, Inc. from 2018 to 2020.
He also held the position of Vice President-Operations & Strategic Alliances at Viracta Therapeutics, Inc. Additionally, he served as Chief Operating Officer at Palisade Bio, Inc. in 2023.
Mr. McRae obtained his undergraduate degree from Wright State University (Ohio).
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
PALISADE BIO, INC.
0.03% | 02/02/2024 | 4 348 ( 0.03% ) | 1 735 $ | 31/03/2024 |
Precedenti posizioni note di Robert McRae
| Società | Posizione | Fine |
|---|---|---|
| PALISADE BIO, INC. | Chief Operating Officer | 01/05/2023 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Operating Officer | - |
Formazione di Robert McRae
| Wright State University (Ohio) | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| PALISADE BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Borsa valori
- Insiders
- Robert McRae
